BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solid Tumors readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Solid Tumors\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06737731-11119@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:SHR-1681: Phase 1/2 readout est. (NCT06737731)
DESCRIPTION:SHR-1681\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Phase I
 /II Clinical Study of SHR-1681 for Injection in Patients With Advanced Sol
 id Tumors\nEstimated primary completion: November 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/shr-1681#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06737731
URL:https://assetmemo.bio/drug/shr-1681#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05784688-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05784688)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of
  TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Adv
 anced Solid Tumors\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05784688
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06605222-11108@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-7787: Phase 1/2 readout est. (NCT06605222)
DESCRIPTION:SHR-7787\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Trial o
 f SHR-7787 Injection in Patients With Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-7787#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06605222
URL:https://assetmemo.bio/drug/shr-7787#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02644369-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02644369)
DESCRIPTION:Pembrolizumab\, phase 2\, Ovarian Cancer.\nStudy: Study of the 
 Effects of Pembrolizumab in Patients With Advanced Solid Tumors\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT02644369
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669430-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05669430)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembro
 lizumab in Participants With Solid Tumor Malignancies\nEstimated primary c
 ompletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05669430
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05491083-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05491083)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Pembrolizumab
  and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05491083
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561362-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04561362)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignanci
 es\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04561362
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298772-11110@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:SHR-4375: Phase 1/2 readout est. (NCT07298772)
DESCRIPTION:SHR-4375\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Study o
 f SHR-4375 Injection in Combination With Other Antitumor Therapies in Pati
 ents With Solid Tumors\nEstimated primary completion: January 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/shr-4375#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07298772
URL:https://assetmemo.bio/drug/shr-4375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549946-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06549946)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: Ixovex-1 Single Agent and Combination Therapy\nEstimated prima
 ry completion: 30 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06549946
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228326-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Maligna
 ncies Affecting the Lungs\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120596-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05120596)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: First in Huma
 n Study of T3P-Y058-739 (T3P)\nEstimated primary completion: 28 February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT051205
 96
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400160-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Clinical Trial of TB511 in Advanced Solid Tumors\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06400160
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04976634-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04976634)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: Pembrolizumab P
 lus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016
 )\nEstimated primary completion: 22 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04976634
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05410145-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05410145)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of D3
 S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid T
 umors With a KRAS p.G12C Mutation\nEstimated primary completion: April 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05410145
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02628067-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02628067)
DESCRIPTION:Pembrolizumab\, phase 2\, Cervical Cancer.\nStudy: Study of Pem
 brolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-1
 58/KEYNOTE-158)\nEstimated primary completion: 4 May 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02628067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastat
 ic Solid Tumors\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06906731-11118@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-9803: Phase 1/2 readout est. (NCT06906731)
DESCRIPTION:SHR-9803\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Study o
 f SHR-9803 for Injection in Patients With Advanced Solid Tumors\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-9803#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06906731
URL:https://assetmemo.bio/drug/shr-9803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732831-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05732831)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Safety and To
 lerability of TNG462 in Patients With MTAP-deleted Solid Tumors\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05732831
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05978102-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05978102)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Dose Escala
 tion and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanc
 ed Solid Tumors\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05978102
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05405595-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05405595)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: ADG126 in Com
 bination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tum
 ors\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05405595
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829254-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03829254)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Safety\, Ph
 armacokinetic and Clinical Activity Study of NUC-7738 in Patients With Adv
 anced Solid Tumours and Lymphoma\nEstimated primary completion: July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03829254
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970497-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05970497)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study Asses
 sing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumor
 s\nEstimated primary completion: July 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05970497
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843550-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07843550)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Phase 1/2 T
 rial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Prev
 iously Treated With Immune Checkpoint Inhibitor Monotherapy\nEstimated pri
 mary completion: 13 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07843550
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843550-2586@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Larotrectinib: Phase 1/2 readout est. (NCT07843550)
DESCRIPTION:Larotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Phase 1/2 T
 rial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Prev
 iously Treated With Immune Checkpoint Inhibitor Monotherapy\nEstimated pri
 mary completion: 13 July 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/larotrectinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07843550
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205706-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06205706)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  BI-1910 as a Single Agent and in Combination With Pembrolizumab for the T
 reatment of Advanced Solid Tumors\nEstimated primary completion: 14 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062057
 06
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438329-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20270813
DTEND;VALUE=DATE:20270814
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438329)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: First-in-huma
 n Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors\nEstimated 
 primary completion: 13 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05438329
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174453-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07174453)
DESCRIPTION:Pembrolizumab\, phase 3\, Solid Tumors.\nStudy: Trial to Evalua
 te irAEs With Different Standard of Care Dosing Strategies of Standard of 
 Care Immunotherapies\nEstimated primary completion: 1 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07174453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04219254-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04219254)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of BI
 -1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tu
 mors\nEstimated primary completion: November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04219254
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04879121-2586@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271111
DTEND;VALUE=DATE:20271112
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT04879121)
DESCRIPTION:Larotrectinib\, phase 2\, Solid Tumors.\nStudy: Larotrectinib f
 or the Treatment of NTRK Amplification Positive\, Locally Advanced or Meta
 static Solid Tumors\nEstimated primary completion: 11 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/larotrectinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04879121
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642780-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05642780)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: SKB264 in Combi
 nation With Pembrolizumab in Subjects With Selected Solid Tumors\nEstimate
 d primary completion: 30 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05642780
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556228-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03556228)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA O
 verexpression Driven Solid Tumors or Lymphoma\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03556228
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158918-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07158918)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: ABL103 in Com
 bination With Pembrolizumab\, With or Without Taxane in Advanced or Metast
 atic Solid Tumors\nEstimated primary completion: 2 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07158918
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795412-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06795412)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Phase 1/2 Stu
 dy of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors\n
 Estimated primary completion: 6 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06795412
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06795412-10913@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271206
DTEND;VALUE=DATE:20271207
SUMMARY:Micvotabart pelidotin: Phase 1/2 readout est. (NCT06795412)
DESCRIPTION:Micvotabart pelidotin\, phase 1/2\, Solid Tumors.\nStudy: Phase
  1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid 
 Tumors\nEstimated primary completion: 6 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06795412
URL:https://assetmemo.bio/drug/micvotabart-pelidotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410494-3251@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:EB-SELECT Single-Target CAR-NK Cells: Phase 1/2 readout est. (NCT07
 410494)
DESCRIPTION:EB-SELECT Single-Target CAR-NK Cells\, phase 1/2\, Solid Tumors
 .\nStudy: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK 
 Cell Therapy for Advanced Solid Tumors\nEstimated primary completion: 28 D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eb-sele
 ct-single-target-car-nk-cells#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07410494
URL:https://assetmemo.bio/drug/eb-select-single-target-car-nk-cells#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410494-3252@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:EB-SELECT Dual-Target CAR-NK Cells: Phase 1/2 readout est. (NCT0741
 0494)
DESCRIPTION:EB-SELECT Dual-Target CAR-NK Cells\, phase 1/2\, Solid Tumors.\
 nStudy: Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Ce
 ll Therapy for Advanced Solid Tumors\nEstimated primary completion: 28 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eb-select
 -dual-target-car-nk-cells#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07410494
URL:https://assetmemo.bio/drug/eb-select-dual-target-car-nk-cells#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438420-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05438420)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Cervical Cancer.\nStudy: Oral Axl/M
 er/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pemb
 rolizumab in Patients With Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 30 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05438420
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07469774-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07469774)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: BC3195 in Com
 bination With Pembrolizumab in Participants With Locally Advanced or Metas
 tatic Solid Tumors\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07469774
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02717156-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT02717156)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: Multicohort Pha
 se II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02717156
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2586@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Larotrectinib\, phase 2\, Solid Tumors.\nStudy: Targeted Therap
 y Directed by Genetic Testing in Treating Patients With Advanced Refractor
 y Solid Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Tria
 l)\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/larotrectinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06771622-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06771622)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Safety and Ef
 ficacy of HCB101 in Combination With Multiple Agents in Patients With Adva
 nced Solid Tumors\nEstimated primary completion: 1 January 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06771622
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02332668-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02332668)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of Pe
 mbrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tum
 or or Lymphoma (MK-3475-051/KEYNOTE-051)\nEstimated primary completion: 2 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02332668
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pe
 mbrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated
  primary completion: 15 February 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415031-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07415031)
DESCRIPTION:Pembrolizumab\, phase 2\, Solid Tumors.\nStudy: A Solid Tumor S
 tudy for Long Term Treatment of Cancer Patients Who Participated in Adagra
 sib Studies\nEstimated primary completion: 16 February 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07415031
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287917-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07287917)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Study of AMXT 1501 and DFMO in Combination With Standard Therapie
 s in Advanced Solid Tumors\nEstimated primary completion: 28 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07287917
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03093116-2264@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Repotrectinib: Phase 1/2 readout est. (NCT03093116)
DESCRIPTION:Repotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Study of Re
 potrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring AL
 K\, ROS1\, or NTRK1-3 Rearrangements\nEstimated primary completion: 29 Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/repotrect
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03093116
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03526835-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03526835)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid T
 umors\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03526835
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101070-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05101070)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: S-531011 as M
 onotherapy and in Combination With an Immune Checkpoint Inhibitor in Advan
 ced or Metastatic Solid Tumors\nEstimated primary completion: 31 May 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05101070
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malign
 ancies\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or 
 Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0497
 7453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160725-11190@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:BMS-986517: Phase 1/2 readout est. (NCT07160725)
DESCRIPTION:BMS-986517\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Phase
  1/2a\, First-in-human\, Study of BMS-986517 in Participants With Advanced
  Solid Tumors\nEstimated primary completion: 31 July 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bms-986517#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07160725
URL:https://assetmemo.bio/drug/bms-986517#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05004116-2264@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Repotrectinib: Phase 1/2 readout est. (NCT05004116)
DESCRIPTION:Repotrectinib\, phase 1/2\, Solid Tumors.\nStudy: A Study of Re
 potrectinib in Combination With Chemotherapy in Children and Young Adults 
 With Solid Tumor Cancer\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/repotrectinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05004116
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Pa
 rticipants With Solid Tumors\nEstimated primary completion: 4 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639450-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07639450)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: N-3C01 Monoth
 erapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors\nEs
 timated primary completion: 31 August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07639450
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197827-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07197827)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of YL
 242 in Subjects With Advanced Solid Tumors\nEstimated primary completion: 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07197827
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tum
 ors\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07446153-11112@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:HRS-8364: Phase 1/2 readout est. (NCT07446153)
DESCRIPTION:HRS-8364\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Clinica
 l Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/hrs-8364#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07446153
URL:https://assetmemo.bio/drug/hrs-8364#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410676-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07410676)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab
  in Advanced Solid Tumors\nEstimated primary completion: 21 December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07410676
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098132-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of STK-012 Alone and With Other Treatments in Patients With Advance
 d Lung Cancer and Other Cancers\nEstimated primary completion: January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05098132
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335497-10868@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:CR-001: Phase 1/2 readout est. (NCT07335497)
DESCRIPTION:CR-001\, phase 1/2\, Solid Tumors.\nStudy: CR-001 in Adult Part
 icipants With Locally Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: February 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/cr-001#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07335497
URL:https://assetmemo.bio/drug/cr-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262619-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07262619)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: EIK1005-
 002: A Clinical Research Study Evaluating EIK1005\, a Werner Helicase Inhi
 bitor\, as Monotherapy and in Combination With Pembrolizumab in Participan
 ts With Advanced Solid Tumors Including Microsatellite Instability High (M
 SI-H) Tumors\nEstimated primary completion: March 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07262619
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07302347-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07302347)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Merkel Cell Carcinoma.\nStudy: A St
 udy of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors 
 or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (M
 K-3475-G21/KEYNOTE-G21)\nEstimated primary completion: 30 March 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07302347
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05394103-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05394103)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Highly Select
 ive CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors\nEstimated prima
 ry completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05394103
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287995-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07287995)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of AS
 P2998 Given by Itself and Given With Standard Therapies in People With Sol
 id Tumors\nEstimated primary completion: 30 June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07287995
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06493552-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT06493552)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Solid Tumors.\nStudy: Modular Trial
  of sEphB4-HSA in EphrinB2-High Solid Tumors\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06493552
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04
  (TP04)]\nEstimated primary completion: 30 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413680-11314@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:REGN10597: Phase 1/2 readout est. (NCT06413680)
DESCRIPTION:REGN10597\, phase 1/2\, Advanced Solid Tumors.\nStudy: A First-
 In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone o
 r in Combination With Cemiplimab Works in Adult Participants Who Have Canc
 er With Tumors That Have Spread in Their Body\nEstimated primary completio
 n: 3 February 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 egn10597#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06413680
URL:https://assetmemo.bio/drug/regn10597#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07730021-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07730021)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study of AS
 P388B Given by Itself and With Standard Therapies in Participants With Sol
 id Tumors\nEstimated primary completion: 28 February 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07730021
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05200559-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05200559)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Ovarian Cancer.\nStudy: T-regulator
 y Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Me
 tastatic Solid Tumors\nEstimated primary completion: 31 May 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05200559
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751042-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20300717
DTEND;VALUE=DATE:20300718
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07751042)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Phase 1/2 Stu
 dy of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monothe
 rapy or in Combination With Pembrolizumab\nEstimated primary completion: 1
 7 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07751042
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of DS-3939a in Participants With Solid Tumors\nEstimated primary 
 completion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07739966
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: A Study to Evaluate the Safety\, Tolerability\, Drug Levels\, and
  Preliminary Efficacy of BMS-986507 Combinations in Adult Participants Wit
 h Advanced Solid Tumors\nEstimated primary completion: 26 February 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749586-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07749586)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: A Study to Ev
 aluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced
  Solid Tumors\nEstimated primary completion: 31 March 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07749586
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533697-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20320218
DTEND;VALUE=DATE:20320219
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05533697)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Solid Tumors.\nStudy: Study of mRNA
 -4359 Administered Alone and in Combination With Immune Checkpoint Blockad
 e in Participants With Advanced Solid Tumors\nEstimated primary completion
 : 18 February 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05533697
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 nti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimat
 ed primary completion: 30 April 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-1973@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03486873)
DESCRIPTION:Pembrolizumab\, phase 3\, Solid Tumors.\nStudy: Long-term Safet
 y and Efficacy Extension Study for Participants With Advanced Tumors Who A
 re Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Stu
 dy (MK-3475-587/KEYNOTE-587)\nEstimated primary completion: 4 August 2043.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03486873-2259@assetmemo.bio
DTSTAMP:20261121T003828Z
DTSTART;VALUE=DATE:20430804
DTEND;VALUE=DATE:20430805
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT03486873)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Solid Tumors.\nStudy: Long-term Safety and Efficacy Extension Study for 
 Participants With Advanced Tumors Who Are Currently on Treatment or in Fol
 low-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)\nEstim
 ated primary completion: 4 August 2043. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT03486873
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
